Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
Houvenaeghel G, de Nonneville A, Chopin N, Classe JM, Mazouni C, Chauvet MP, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher JM. Houvenaeghel G, et al. Among authors: mazouni c. Cancer Med. 2023 Feb;12(4):4023-4032. doi: 10.1002/cam4.5257. Epub 2022 Sep 20. Cancer Med. 2023. PMID: 36127853 Free PMC article.
Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study.
Chéreau E, Uzan C, Boutmy-Deslandes E, Zohar S, Bézu C, Mazouni C, Garbay JR, Daraï E, Rouzier R. Chéreau E, et al. Among authors: mazouni c. PLoS One. 2016 Jun 9;11(6):e0156096. doi: 10.1371/journal.pone.0156096. eCollection 2016. PLoS One. 2016. PMID: 27280398 Free PMC article. Clinical Trial.
Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTEGS study.
Rouzier R, Uzan C, Rousseau A, Guillot E, Zilberman S, Meyer C, Estevez P, Dupre PF, Kere D, Doridot V, D'halluin G, Fritel X, Pouget N, Jankowski C, Mazouni C, Simon T, Coutant C. Rouzier R, et al. Among authors: mazouni c. Br J Cancer. 2017 Apr 25;116(9):1135-1140. doi: 10.1038/bjc.2017.47. Epub 2017 Mar 21. Br J Cancer. 2017. PMID: 28324891 Free PMC article. Clinical Trial.
Sentinel lymph node biopsy validation for large tumors.
Houvenaeghel G, Quilichini O, Cohen M, Reyal F, Classe JM, Mazouni C, Giard S, Carrabin N, Charitansky H, Darai E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon-DE-Lara C, Lambaudie E. Houvenaeghel G, et al. Among authors: mazouni c. Int J Surg. 2017 Dec;48:275-280. doi: 10.1016/j.ijsu.2017.10.077. Epub 2017 Nov 24. Int J Surg. 2017. PMID: 29175020 Free article.
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.
Houvenaeghel G, de Nonneville A, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo PE, Gimbergues P, Chauvet MP, Azuar AS, Rouzier R, de Lara CT, Muracciole X, Agostini A, Gonçalves A, Lambaudie E. Houvenaeghel G, et al. Among authors: mazouni c. Breast Cancer Res Treat. 2019 Jan;173(1):111-122. doi: 10.1007/s10549-018-4944-2. Epub 2018 Sep 20. Breast Cancer Res Treat. 2019. PMID: 30238274
Lymph node positivity in different early breast carcinoma phenotypes: a predictive model.
Houvenaeghel G, Lambaudie E, Classe JM, Mazouni C, Giard S, Cohen M, Faure C, Charitansky H, Rouzier R, Daraï E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Fraisse J, Dravet F, Chauvet MP, Boher JM. Houvenaeghel G, et al. Among authors: mazouni c. BMC Cancer. 2019 Jan 10;19(1):45. doi: 10.1186/s12885-018-5227-3. BMC Cancer. 2019. PMID: 30630443 Free PMC article.
Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.
de Nonneville A, Jauffret C, Gonçalves A, Classe JM, Cohen M, Reyal F, Mazouni C, Chauvet MP, Chopin N, Colombo PE, Jouve E, Darai E, Rouzier R, Coutant C, Gimbergues P, Azuar AS, de Lara CT, Lambaudie E, Houvenaeghel G. de Nonneville A, et al. Among authors: mazouni c. Breast Cancer Res Treat. 2019 Jun;175(2):379-387. doi: 10.1007/s10549-019-05160-9. Epub 2019 Feb 13. Breast Cancer Res Treat. 2019. PMID: 30759288 Clinical Trial.
131 results